Roberta Diaz Brinton, PhD

Roberta Diaz Brinton, PhD, director of the University of Arizona Center for Innovation in Brain Science(CIBS) will be honored as the Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association (AZBio) at the 2022 AZBio Awards event Sept. 28 at the Phoenix Convention Center.

Dr. Brinton is a Regents Professor of Pharmacology with an additional appointment in neurology in the UArizona College of Medicine – Tucson and a member of BIO5 Institute. She returned to her alma mater in 2016 to create CIBS, a hybrid university/biotech research center designed to advance cures for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis, or ALS, through integrated discovery, translational and clinical science. Since its inception, CIBS has received more than $112 million in grants to advance cures for these neurodegenerative diseases.Continue reading→

– Aqualung will continue the P1A Healthy Human Volunteer Trial and complete the trial first half of 2023
– The Phase 2A study (PUERTA) will be initiated in the 2^nd half of 2023
– ALT-100 is the first humanized mAb therapy that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosisContinue reading→

PHOENIX—September 26, 2022—A deep dive into the proteins and protein activities of human tumors grown in mouse models expands the potential therapeutic pathways to treat medulloblastoma, according to a new study published in the Journal of Proteome Research. Continue reading→

The path for a cure for cancer will run through Phoenix.

Sit down with Phoenix Mayor Kate Gallego and bring up the subject of biosciences, you will experience a burst of energy and insight about the innovation in healthcare taking place across Phoenix, including the growth of businesses creating jobs, and a personal passion that, “the path for a cure for cancer will run through Phoenix.”Continue reading→

New Microfluidics Platform with embedded Stretchable Microelectrodes for Research on Alzheimer’s Disease and other Neurological and Neurodegenerative DiseasesContinue reading→

MADISON, Wis., Sept. 22, 2022 — Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.Continue reading→

PHOENIX—September 22, 2022—Vidium Animal Health announced today that it has entered a reseller agreement with Antech Diagnostics to provide SearchLight DNA^Ⓡ, the best-in-class genomic diagnostic for cancer in dogs, to Antech’s large North American customer base. Genomic diagnostics in general, and SearchLight DNA in particular, are a key part of expanding the use of personalized medicine in canine patients.
Continue reading→

TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial Hypertension (PAH) and Inflammatory Bowel Disease (IBD). The ALT-100 mAb targets the inflammation-inducing damage-associated molecular pattern protein eNAMPT, and is currently in Phase 1A human safety trials.

Continue reading→

By Steve Potts, PhD

The new Inflation Reduction Act was written in part to improve access to prescription drugs. But just like many potent drugs, the law too has side effects. As a small biotech drug developer, here’s the most toxic: It’s forcing me to choose to develop a drug for kids instead of a drug for their grandparents, when I could be developing both.Continue reading→

In 2022, ACS CAN led a successful legislative campaign in Arizona to expand access to biomarker testing. Gov. Ducey, Rep. Regina Cobb, Dr. Rachna Shroff and Holly Hill reflect on the impact this law will have on patients across the state.

Continue reading→